Holen Sie sich die Stockscreener-App
0.5052
9.43%
-0.0526
Handel nachbörslich:
.51
0.0048
+0.95%
Schlusskurs vom Vortag:
$0.5578
Offen:
$0.56
24-Stunden-Volumen:
1.81M
Relative Volume:
1.39
Marktkapitalisierung:
$38.85M
Einnahmen:
$4.72B
Nettoeinkommen (Verlust:
$-123.85M
KGV:
-0.0353
EPS:
-14.2981
Netto-Cashflow:
$-303.12M
1W Leistung:
-28.64%
1M Leistung:
-56.82%
6M Leistung:
-80.79%
1J Leistung:
-82.02%
1-Tages-Spanne:
$0.50
$0.5745
1-Wochen-Bereich:
$0.50
$0.71
52-Wochen-Spanne:
$0.50
$4.6887
Accendra Health Inc Stock (ACH) Company Profile
Firmenname
Accendra Health Inc
Sektor
Branche
Telefon
(804) 277-4304
Adresse
4435 WATERFRONT DRIVE, GLEN ALLEN
Compare ACH vs MCK, COR, CAH, HSIC, AHG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACH
Accendra Health Inc
|
0.5052 | 54.45M | 4.72B | -123.85M | -303.12M | -14.30 |
MCK
Mckesson Corp
|
902.28 | 101.04B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
309.05 | 58.57B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
228.30 | 50.99B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
84.88 | 9.63B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.15 | 642.53M | 14.85M | -136.07M | 7.25M | -0.4726 |
Accendra Health Inc Stock (ACH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Herabstufung | UBS | Buy → Neutral |
| 2024-07-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-13 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-12 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-04-26 | Fortgesetzt | Citigroup | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-30 | Fortgesetzt | JP Morgan | Underweight |
| 2022-03-23 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2021-04-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-17 | Hochstufung | UBS | Neutral → Buy |
| 2020-09-25 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-07-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-07-14 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-05-05 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-01-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-01-07 | Herabstufung | Goldman | Neutral → Sell |
| 2019-11-15 | Hochstufung | CLSA | Underperform → Outperform |
| 2019-09-06 | Bestätigt | BofA/Merrill | Neutral |
| 2019-04-10 | Bestätigt | BofA/Merrill | Neutral |
| 2019-04-03 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-01 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-01-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-15 | Hochstufung | CLSA | Underperform → Outperform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2018-12-12 | Herabstufung | Goldman | Buy → Neutral |
| 2018-09-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-11 | Herabstufung | CLSA | Outperform → Sell |
| 2018-04-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-26 | Hochstufung | Goldman | Sell → Neutral |
| 2017-11-02 | Herabstufung | HSBC Securities | Buy → Hold |
| 2016-03-24 | Hochstufung | Goldman | Sell → Neutral |
| 2015-12-07 | Herabstufung | Goldman | Neutral → Sell |
| 2015-08-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2012-08-01 | Eingeleitet | HSBC Securities | Underweight |
| 2009-08-05 | Hochstufung | Citigroup | Sell → Buy |
| 2008-12-01 | Herabstufung | HSBC Securities | Neutral → Underweight |
Alle ansehen
Accendra Health Inc Aktie (ACH) Neueste Nachrichten
Lobbying Update: $200,000 of ACCENDRA HEALTH INC. lobbying was just disclosed - Quiver Quantitative
Henrico-based Owens & Minor to close production facility, cut 400 jobs - Richmond Times-Dispatch
Accendra Health, Inc. $ACH Shares Newly Bought by Bank of America Corp DE - MarketBeat
ACH News | ACCENDRA HEALTH INC (NYSE:ACH) - ChartMill
Owens & Minor stock falls as Accendra Health resets its identity - AD HOC NEWS
Form 4 Accendra Health Inc For: 24 September By Investing.com - Investing.com South Africa
Accendra Health (ACH) CFO surrenders shares for taxes tied to stock vesting; he holds 286,268 shares afterward. - Stock Titan
Accendra Health names new CEO, chief commercial officer - Richmond Times-Dispatch
Accendra Health appoints new CEO and commercial chief - The Globe and Mail
Accendra Health names Kenneth Gardner-Smith as next CEO By Investing.com - Investing.com Nigeria
Accendra Health Names Kenneth Gardner-Smith as President and Chi - GuruFocus
Accendra Health Names Kenneth Gardner-Smith CEO, Adds Chief Commercial Officer - citybiz
Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth - Business Wire
Accendra Health Inc. (ACH) Slips 3.15% to $1.07 as Shares Drift Toward Lower SupportInverse ETF Flow - dars.gov.et
BlackRock Inc. Acquires New Stake in Accendra Health, Inc. $ACH - MarketBeat
Accendra Health (ACH) Holds Steady at $1.21 as Shares Trade Within Defined Support and Resistance RangeRVOL Spike - dars.gov.et
Accendra Health Inc (NYSE: ACH) Share Price, ACH Stock News, ACH Share Price & Updates - Kalkine
Connor Clark & Lunn Investment Management Ltd. Invests $4.41 Million in Accendra Health, Inc. $ACH - MarketBeat
2,536,699 Shares in Accendra Health, Inc. $ACH Purchased by Paradigm Capital Management Inc. NY - MarketBeat
Accendra (ACH) Latest Quarter: EPS Does Not Reach the Reported Estimate in the Reported Period; Closing Reaction: The Share Price Sheds 4.67% at the CloseEarnings Surprise Report - vinanet.vn
Accendra (ACH) Quarterly Figures: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Stock Move: The Stock Gains 5.61% for the Current SessionBasic EPS Analysis - vinanet.vn
Accendra Health scraps equity program, expects CEO successor By Investing.com - Investing.com South Africa
Accendra Health Inc (ACH) (Q2 2026) Earnings Call Highlights: Na - GuruFocus
Accendra Health provides update on CEO transition, credit facility - HME News
symbol__ Stock Quote Price and Forecast - CNN
Accendra Health Drops Equity Issuance Plan, Targets September CEO Announcement - citybiz
Accendra Health drops equity issuance plan as CEO succession process advances - Yahoo Finance
Accendra Health scraps equity program, expects CEO successor - Investing.com
Form 8K Accendra Health Inc For: 17 August By Investing.com - Investing.com Nigeria
Accendra Health sells first of two non-core assets, expects about $45 million cash injection - Bitget
Accendra Health to forgo ATM program, sees ~$45M from two asset sales; CEO successor expected by mid-September - TradingView
Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans - Yahoo Finance
Accendra Health ready to put weak Q2 in rear view - HME News
Accendra Health (ACH) Drops 9% to $1.10 as Selling Pressure PersistsAnchored VWAP - vinanet.vn
Accendra Health (NYSE:ACH) Rating Lowered to "Hold" at Robert W. Baird - MarketBeat
Dimensional Fund Advisors LP Buys Shares of 2,606,620 Accendra Health, Inc. $ACH - MarketBeat
Accendra Health (ACHC) Stock Sinks As Losses Deepen And Cash Stays Tight - Simply Wall Street
Accendra Health, Inc. (ACH) stock price, news, quote and history - Yahoo Finance UK
Baird downgrades Accendra Health stock rating on weak results By Investing.com - Investing.com South Africa
Accendra Health, Inc. (ACH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Accendra Health adopts tax asset preservation plan - HME News
Accendra Health's Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search - marketscreener.com
Citigroup Downgrades Accendra Health to Neutral From Buy, Adjusts PT to $1.50 From $4.50 - marketscreener.com
Baird Downgrades Accendra Health to Neutral From Outperform, Adjusts PT to $1.50 From $6 - marketscreener.com
ACCENDRA HEALTH INC : BAIRD CUTS TO NEUTRAL RATING; CUTS TARGET PRICE TO $1.5 FROM $6 - Bitget
Baird downgrades Accendra Health stock rating on weak results - Investing.com
Accendra Health Chief Executive Edward Pesicka to Retire - Moomoo
Finanzdaten der Accendra Health Inc-Aktie (ACH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.58%
12.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):